Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Brigatinib CAS 1197953-54-0 Raw Materials Powder
Product Overview:
Brigatinib Powder is a next-generation tyrosine kinase inhibitor with significant efficacy in ALK+ metastatic NSCLC, Brigatinib CAS 1197953-54-0 for the treatment of mesenchymal lymphoma kinase (ALK)-positive non-small cell lung cancer and in patients whose disease has progressed after crizotinib (Crizotinib) therapy or is not On August 30, 2016, the FDA granted brigatinib breakthrough therapy and rare drug status for the treatment of ALK+NSCLC to patients whose first-generation ALK+NSCLC treatment, crizotinib, has progressed or is not tolerated, granting priority review of the marketing application and allowing for a rolling submission of the application materials.The FDA approved Brigatinib Raw Materials on April 28, 2017 Brigatinib Raw Materials to market under the trade name Alunbrigtm.
Brigatinib CAS 1197953-54-0 Raw Materials Powder Attributes
CAS: 1197953-54-0
MF: C29H39ClN7O2P
MW: 584.09
EINECS: 1592732-453-0
Specification: 99% min Brigatinib
Sample: Brigatinib Powder
Brand: Henrikang
Appearance: White Powder
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Brigatinib CAS 1197953-54-0 Raw Materials Powder Details
Brigatinib Powder Usage and Synthesis.
Brigatinib Powder is a next-generation tyrosine kinase inhibitor with significant efficacy in ALK+ metastatic NSCLC,
Brigatinib CAS 1197953-54-0 for the treatment of mesenchymal lymphoma kinase (ALK)-positive non-small cell lung cancer and in patients whose disease has progressed after crizotinib (Crizotinib) therapy or is not On August 30, 2016, the FDA granted brigatinib breakthrough therapy and rare drug status for the treatment of ALK+NSCLC to patients whose first-generation ALK+NSCLC treatment, crizotinib, has progressed or is not tolerated, granting priority review of the marketing application and allowing for a rolling submission of the application materials.
The FDA approved Brigatinib Raw Materials on April 28, 2017 Brigatinib Raw Materials to market under the trade name Alunbrigtm.
Application/Function of Brigatinib Powder.
Brigatinib Powder is a tyrosine kinase receptor (MERTK) inhibitor that can be used in combination with epidermal growth factor receptor (EGFR) inhibitors for cancer treatment.
Brigatinib Raw Materials are tyrosine kinase inhibitors. Bugtinib is indicated for patients with AlK-positive metastatic NSCLC who cannot tolerate crizotinib treatment or whose disease has progressed. This indication is approved on an accelerated basis based on tumor response rate and duration of response, and subsequent approval of the indication may depend on confirmation of further clinical trials and description of clinical benefit.
Brigatinib (AP26113) is a potent and selective ALK inhibitor with IC50=0.6 nM; Also a ROS1 inhibitor, IC50=0.9 nM. It also inhibits IGF-1R, FLT3, FLT3(D835Y), and EGFR with relatively low potency.
